

Celsion Corporation Investor Relations Department 997 Lenox Drive Suite 100 Lawrenceville, NJ 08648 United States

Visit IR website ☐ Sign-up for Email alerts ☐ ☐

NASDAQ: CLSN	
Last Trade:	1.85
Trade Time:	4:00 PM ET Jul 21, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	1.81 - 19.61
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Celsion Corporation is an oncology drug development company focused on the development of efficient, effective, and targeted therapies for the treatment of cancer. Founded in 1985, the company has developed elegant therapeutic approaches that deliver high concentrations of widely used anti-cancer agents directly to the tumor site, maximizing efficacy while minimizing the sideeffects of systemic treatments, with the goal of improving patient outcomes in underserved cancer indications. The foundation for this research is a heatsensitive liposomal nanoparticle licensed from Duke Universit... (more)

Stock Performance



Press Releases [View all]

Jul 6, 2017

<u>Celsion Corporation Announces \$5 Million</u> <u>Registered Direct Offering</u>

Jul 5, 2017

Celsion Announces Completion of OVATION
Study and Provides Update on its
Immunotherapy Trial in Advanced Stage III
and IV Ovarian Cancer

Jun 22, 2017

<u>Celsion Corporation Announces Cancellation</u> of Registered Direct Offering

Jun 19, 2017

<u>Celsion Corporation Announces \$5.4 Million</u> <u>Registered Direct Offering</u>

Jun 14, 2017

<u>Celsion Corporation Regains Compliance with</u> <u>NASDAQ Listing Requirements</u>

Financials [View all]

First Quarter Financial Results

Mar 24, 2017

Annual Report (10-K)

Apr 4, 2017

Proxy Statement (DEF 14A)

May 12, 2017

Quarterly Report (10-Q)

Nov 10, 2016

Quarterly Report (10-Q)

Aug 15, 2016

Quarterly Report (10-Q)